David Delaney - 17 Oct 2022 Form 4 Insider Report for Pasithea Therapeutics Corp. (KTTA)

Reporting relationship: Member of 10% owner group
Issuer ticker: KTTA
Reported as of: 17 Oct 2022
Net transaction value: +$1,110
SEC form: 4
Accepted by SEC: 19 Oct 2022, 17:29:22 UTC
Prior SEC filing: 16 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ David Delaney

Key filing fact

David Delaney filed Form 4 for Pasithea Therapeutics Corp. (KTTA) on 19 Oct 2022.

Key facts

This page summarizes David Delaney's Form 4 filing for Pasithea Therapeutics Corp. (KTTA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Oct 2022, 17:29.

Change

Previous filing in this sequence was filed on 16 Aug 2022.
Current net transaction value: +$1,110.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KTTA transaction

Common Stock

Purchase

Transaction value: $1,110
Shares: +1,000
Change %: +0.44%
Price: $1.11
Shares after: 227,521
Date: 17 Oct 2022
Ownership: See footnote
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares were purchased by Elderhill Corporation, of which David Delaney serves as sole director and President.

Footnote F2

191,321 shares are held by Concord IP2, Ltd., of which David Delaney serves as sole director and President, and 36,200 shares are held by Elderhill Corporation.